These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15094232)

  • 21. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
    Tsubota A; Arase Y; Suzuki F; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
    J Gastroenterol; 2004; 39(2):155-61. PubMed ID: 15069622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
    Tomimatsu M; Aizawa Y; Chuganji Y; Ishizuka H; Fujita Y; Aizawa R; Abe H; Matsuda T; Itou Y; Nakanishi H; Ushiyama H; Higuchi T; Fujimoto T; Endou H; Iga D; Ohta K; Kuroda H
    J Gastroenterol Hepatol; 2006 Jul; 21(7):1177-83. PubMed ID: 16824072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
    Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
    J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.
    Asahina Y; Izumi N; Umeda N; Hosokawa T; Ueda K; Doi F; Tsuchiya K; Nakanishi H; Matsunaga K; Kitamura T; Kurosaki M; Uchihara M; Higaki M; Miyake S
    J Viral Hepat; 2007 Jun; 14(6):396-403. PubMed ID: 17501760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dynamics of serum hepatitis C virus load and quasispecies complexity during antiviral therapy in patients with chronic hepatitis C.
    Grahovac B; Bingulac-Popovic J; Vucelic B; Hrstic I; Ostojic R; Drazic V; Balija M; Grgicevic D
    J Clin Virol; 2001 Jan; 20(1-2):85-9. PubMed ID: 11163588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia.
    Jovanovic-Cupic S; Glisic S; Stanojevic M; Nozic D; Petrovic N; Mandusic V; Krajnovic M
    Arch Virol; 2016 May; 161(5):1189-98. PubMed ID: 26860912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
    Crespo M; Esteban JI; Ribera E; Falco V; Sauleda S; Buti M; Esteban R; Guardia J; Ocaña I; Pahissa A
    AIDS; 2007 Feb; 21(4):477-81. PubMed ID: 17301566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of three successive antiviral treatments on viral heterogeneity in nonresponder chronic hepatitis C patients.
    Thelu MA; Brengel-Pesce K; Leroy V; Attuil V; Drouet E; Seigneurin JM; Zarski JP
    J Med Virol; 2001 Dec; 65(4):698-705. PubMed ID: 11745934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
    Abe H; Aida Y; Ishiguro H; Yoshizawa K; Seki N; Miyazaki T; Itagaki M; Sutoh S; Ika M; Kato K; Shimada N; Tsubota A; Aizawa Y
    J Med Virol; 2013 Sep; 85(9):1523-33. PubMed ID: 23775277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of a new immunoradiometric assay of HCV core antigen to predict virological response during PEG-IFN/RBV combination therapy for chronic hepatitis with high viral load of serum HCV RNA genotype 1b.
    Sasase N; Kim SR; Kim KI; Taniguchi M; Imoto S; Mita K; Hotta H; Shouji I; El-Shamy A; Kawada N; Kudo M; Hayashi Y
    Intervirology; 2008; 51 Suppl 1():70-5. PubMed ID: 18544951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quasispecies as predictive response factors for antiviral treatment in patients with chronic hepatitis C.
    Salmerón J; De Rueda PM; Ruiz-Extremera A; Casado J; Huertas C; Bernal Mdel C; Rodríguez L; Palacios A
    Dig Dis Sci; 2006 May; 51(5):960-7. PubMed ID: 16758308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C.
    Gerotto M; Sullivan DG; Polyak SJ; Chemello L; Cavalletto L; Pontisso P; Alberti A; Gretch DR
    J Virol; 1999 Sep; 73(9):7241-7. PubMed ID: 10438811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy.
    Sandres K; Dubois M; Pasquier C; Payen JL; Alric L; Duffaut M; Vinel JP; Pascal JP; Puel J; Izopet J
    J Virol; 2000 Jan; 74(2):661-8. PubMed ID: 10623727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolution of hepatitis C virus quasispecies during ribavirin and interferon-alpha-2b combination therapy and interferon-alpha-2b monotherapy.
    Arataki K; Kumada H; Toyota K; Ohishi W; Takahashi S; Tazuma S; Chayama K
    Intervirology; 2006; 49(6):352-61. PubMed ID: 16926548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C.
    Puig-Basagoiti F; Forns X; Furčić I; Ampurdanés S; Giménez-Barcons M; Franco S; Sánchez-Tapias JM; Saiz JC
    J Gen Virol; 2005 Apr; 86(Pt 4):1067-1075. PubMed ID: 15784900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy.
    Pawlotsky JM; Germanidis G; Frainais PO; Bouvier M; Soulier A; Pellerin M; Dhumeaux D
    J Virol; 1999 Aug; 73(8):6490-9. PubMed ID: 10400744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Current options for predicting therapeutic response in chronically infected patients with hepatitis C virus genotype 1].
    Saludes Montoro V; Ausina Ruiz V; Martró Català E
    Enferm Infecc Microbiol Clin; 2011 Dec; 29 Suppl 5():51-8. PubMed ID: 22305670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment.
    Jain MK; Yuan HJ; Adams-Huet B; Reeck A; Shelton J; Attar N; Zhang S; Neumann AU; Carney DS; Gale M; Lee WM
    J Infect Dis; 2009 Sep; 200(6):866-76. PubMed ID: 19673650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis C virus quasispecies and response to interferon therapy in patients with chronic hepatitis C: a prospective study.
    Hino K; Yamaguchi Y; Fujiwara D; Katoh Y; Korenaga M; Okazaki M; Okuda M; Okita K
    J Viral Hepat; 2000 Jan; 7(1):36-42. PubMed ID: 10718941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of increasing dose of interferon on the evolution of hepatitis C virus 1b quasispecies.
    De Mitri MS; Mele L; Morsica G; Chen CH; Sitia G; Gramenzi A; Andreone P; Alberti A; Bernardi M; Pisi E
    J Med Virol; 2000 Feb; 60(2):133-8. PubMed ID: 10596011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.